UA73476C2 - Hepatitus b mutant virus strain, nucleic acid isolated molecule, coding mutant main surface antigen of hepatitus b virus strain, vector and vector system for the preparation of polypeptide, a method for the preparation of polypeptide (variants), purified polypeptide (variants), oligonucleotide, a method for the preparation of antibodies (variants), antibody (variants), a method for the determination of chemicalcompound for the treatment of infection of hepatitis virus strain, a composition, a method for screening of liquids of organism for hepatitis b virus, vaccine against hepatitis - Google Patents
Hepatitus b mutant virus strain, nucleic acid isolated molecule, coding mutant main surface antigen of hepatitus b virus strain, vector and vector system for the preparation of polypeptide, a method for the preparation of polypeptide (variants), purified polypeptide (variants), oligonucleotide, a method for the preparation of antibodies (variants), antibody (variants), a method for the determination of chemicalcompound for the treatment of infection of hepatitis virus strain, a composition, a method for screening of liquids of organism for hepatitis b virus, vaccine against hepatitis Download PDFInfo
- Publication number
- UA73476C2 UA73476C2 UA2000127297A UA2000127297A UA73476C2 UA 73476 C2 UA73476 C2 UA 73476C2 UA 2000127297 A UA2000127297 A UA 2000127297A UA 2000127297 A UA2000127297 A UA 2000127297A UA 73476 C2 UA73476 C2 UA 73476C2
- Authority
- UA
- Ukraine
- Prior art keywords
- polypeptide
- virus
- amino acid
- hepatitis
- surface antigen
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 298
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 248
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 244
- 241000700721 Hepatitis B virus Species 0.000 title claims abstract description 199
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 130
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 125
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 125
- 238000000034 method Methods 0.000 title claims abstract description 51
- 108091007433 antigens Proteins 0.000 title claims description 72
- 102000036639 antigens Human genes 0.000 title claims description 71
- 239000000427 antigen Substances 0.000 title claims description 70
- 150000001875 compounds Chemical class 0.000 title claims description 44
- 108091034117 Oligonucleotide Proteins 0.000 title claims description 34
- 229960005486 vaccine Drugs 0.000 title claims description 29
- 241000700605 Viruses Species 0.000 title claims description 27
- 239000013598 vector Substances 0.000 title claims description 25
- 239000000203 mixture Substances 0.000 title claims description 24
- 208000015181 infectious disease Diseases 0.000 title claims description 17
- 238000011282 treatment Methods 0.000 title claims description 10
- 238000012216 screening Methods 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title description 7
- 208000006454 hepatitis Diseases 0.000 title description 4
- 231100000283 hepatitis Toxicity 0.000 title description 4
- 239000007788 liquid Substances 0.000 title description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 96
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 96
- 239000004473 Threonine Substances 0.000 claims abstract description 96
- 229930182817 methionine Natural products 0.000 claims abstract description 96
- 101710084021 Large envelope protein Proteins 0.000 claims abstract description 91
- 239000002773 nucleotide Substances 0.000 claims abstract description 44
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 44
- 150000001413 amino acids Chemical group 0.000 claims abstract description 38
- 230000003612 virological effect Effects 0.000 claims abstract description 16
- 238000004113 cell culture Methods 0.000 claims abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 175
- 125000000539 amino acid group Chemical group 0.000 claims description 47
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 44
- 108020004999 messenger RNA Proteins 0.000 claims description 28
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 22
- 108020004414 DNA Proteins 0.000 claims description 19
- 238000001514 detection method Methods 0.000 claims description 18
- 210000002966 serum Anatomy 0.000 claims description 16
- 101710123661 Venom allergen 5 Proteins 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims description 13
- 206010073069 Hepatic cancer Diseases 0.000 claims description 13
- 201000002250 liver carcinoma Diseases 0.000 claims description 13
- 230000027455 binding Effects 0.000 claims description 8
- 239000003550 marker Substances 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 210000001124 body fluid Anatomy 0.000 claims description 7
- 239000010839 body fluid Substances 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 208000002672 hepatitis B Diseases 0.000 claims description 6
- 238000002955 isolation Methods 0.000 claims description 6
- 230000009870 specific binding Effects 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 5
- 238000009396 hybridization Methods 0.000 claims description 5
- 230000003053 immunization Effects 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000009918 complex formation Effects 0.000 claims description 4
- 238000002649 immunization Methods 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 238000013519 translation Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000000890 antigenic effect Effects 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 241000239366 Euphausiacea Species 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 229960002520 hepatitis vaccine Drugs 0.000 claims 1
- 230000016784 immunoglobulin production Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 239000000470 constituent Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 27
- 239000000523 sample Substances 0.000 description 27
- 230000035772 mutation Effects 0.000 description 17
- 231100000350 mutagenesis Toxicity 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 9
- 108020005202 Viral DNA Proteins 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 108010067390 Viral Proteins Proteins 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 239000000969 carrier Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003443 antiviral agent Substances 0.000 description 4
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000032 diagnostic agent Substances 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940021747 therapeutic vaccine Drugs 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101710173438 Late L2 mu core protein Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 229940021993 prophylactic vaccine Drugs 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 241000786798 Atya Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 101710175243 Major antigen Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000003995 blood forming stem cell Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 101100291267 Drosophila melanogaster Miga gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101150063042 NR0B1 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000599304 Rhorus Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 101150003160 X gene Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000034184 interaction with host Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- -1 olive oil Chemical compound 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000011451 sequencing strategy Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SG1998/000046 WO1999066048A1 (en) | 1998-06-19 | 1998-06-19 | A mutant human hepatitis b viral strain and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA73476C2 true UA73476C2 (en) | 2005-08-15 |
Family
ID=20429862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2000127297A UA73476C2 (en) | 1998-06-19 | 1998-06-19 | Hepatitus b mutant virus strain, nucleic acid isolated molecule, coding mutant main surface antigen of hepatitus b virus strain, vector and vector system for the preparation of polypeptide, a method for the preparation of polypeptide (variants), purified polypeptide (variants), oligonucleotide, a method for the preparation of antibodies (variants), antibody (variants), a method for the determination of chemicalcompound for the treatment of infection of hepatitis virus strain, a composition, a method for screening of liquids of organism for hepatitis b virus, vaccine against hepatitis |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6558675B1 (no) |
| EP (1) | EP1098981A1 (no) |
| JP (1) | JP2002518014A (no) |
| KR (1) | KR100498118B1 (no) |
| CN (1) | CN1322251A (no) |
| AR (1) | AR020093A1 (no) |
| AU (1) | AU756866B2 (no) |
| BG (1) | BG105066A (no) |
| BR (1) | BR9815913A (no) |
| CA (1) | CA2330935C (no) |
| HU (1) | HUP0103409A3 (no) |
| IL (1) | IL140364A0 (no) |
| IS (1) | IS5778A (no) |
| MX (1) | MXPA00012720A (no) |
| MY (1) | MY118955A (no) |
| NO (1) | NO20006456L (no) |
| NZ (1) | NZ508890A (no) |
| PL (1) | PL192129B1 (no) |
| TR (1) | TR200003777T2 (no) |
| UA (1) | UA73476C2 (no) |
| WO (1) | WO1999066048A1 (no) |
| YU (1) | YU80600A (no) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200643171A (en) * | 2005-06-07 | 2006-12-16 | Temasek Life Sciences Lab Ltd | Porcine circovirus type 2 vaccines |
| CN117843811A (zh) | 2019-09-30 | 2024-04-09 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| CN113201051B (zh) * | 2021-04-27 | 2022-08-02 | 复旦大学 | 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9401987D0 (en) | 1994-02-02 | 1994-03-30 | Imperial College | Modified nucleic acid |
| AU4353897A (en) | 1996-09-18 | 1998-04-14 | Board Of Regents, The University Of Texas System | Viral defective interfering particles and uses thereof |
-
1998
- 1998-06-19 CA CA002330935A patent/CA2330935C/en not_active Expired - Fee Related
- 1998-06-19 UA UA2000127297A patent/UA73476C2/uk unknown
- 1998-06-19 IL IL14036498A patent/IL140364A0/xx unknown
- 1998-06-19 NZ NZ508890A patent/NZ508890A/en unknown
- 1998-06-19 HU HU0103409A patent/HUP0103409A3/hu unknown
- 1998-06-19 CN CN98814201A patent/CN1322251A/zh active Pending
- 1998-06-19 PL PL345573A patent/PL192129B1/pl not_active IP Right Cessation
- 1998-06-19 WO PCT/SG1998/000046 patent/WO1999066048A1/en not_active Application Discontinuation
- 1998-06-19 EP EP98926023A patent/EP1098981A1/en not_active Withdrawn
- 1998-06-19 YU YU80600A patent/YU80600A/sh unknown
- 1998-06-19 AU AU77951/98A patent/AU756866B2/en not_active Ceased
- 1998-06-19 BR BR9815913-5A patent/BR9815913A/pt not_active Application Discontinuation
- 1998-06-19 TR TR2000/03777T patent/TR200003777T2/xx unknown
- 1998-06-19 JP JP2000554857A patent/JP2002518014A/ja active Pending
- 1998-06-19 KR KR10-2000-7014456A patent/KR100498118B1/ko not_active IP Right Cessation
- 1998-06-19 MX MXPA00012720A patent/MXPA00012720A/es not_active Application Discontinuation
- 1998-06-19 US US09/719,528 patent/US6558675B1/en not_active Expired - Fee Related
-
1999
- 1999-06-18 AR ARP990102962A patent/AR020093A1/es unknown
- 1999-06-18 MY MYPI99002517A patent/MY118955A/en unknown
-
2000
- 2000-12-18 NO NO20006456A patent/NO20006456L/no not_active Application Discontinuation
- 2000-12-18 BG BG105066A patent/BG105066A/xx unknown
- 2000-12-19 IS IS5778A patent/IS5778A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2330935C (en) | 2005-05-10 |
| EP1098981A1 (en) | 2001-05-16 |
| JP2002518014A (ja) | 2002-06-25 |
| PL345573A1 (en) | 2001-12-17 |
| WO1999066048A1 (en) | 1999-12-23 |
| CA2330935A1 (en) | 1999-12-23 |
| HUP0103409A3 (en) | 2003-10-28 |
| PL192129B1 (pl) | 2006-09-29 |
| IS5778A (is) | 2000-12-19 |
| IL140364A0 (en) | 2002-02-10 |
| KR20010106129A (ko) | 2001-11-29 |
| NO20006456D0 (no) | 2000-12-18 |
| MY118955A (en) | 2005-02-28 |
| MXPA00012720A (es) | 2002-05-08 |
| NZ508890A (en) | 2004-04-30 |
| TR200003777T2 (tr) | 2001-06-21 |
| AR020093A1 (es) | 2002-04-10 |
| BR9815913A (pt) | 2001-12-26 |
| HUP0103409A2 (hu) | 2001-12-28 |
| NO20006456L (no) | 2001-02-16 |
| BG105066A (en) | 2001-09-28 |
| KR100498118B1 (ko) | 2005-07-01 |
| CN1322251A (zh) | 2001-11-14 |
| AU7795198A (en) | 2000-01-05 |
| US6558675B1 (en) | 2003-05-06 |
| YU80600A (sh) | 2005-06-10 |
| AU756866B2 (en) | 2003-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Serçe et al. | Further characterization of a new recombinant group of Plum pox virus isolates, PPV-T, found in orchards in the Ankara province of Turkey | |
| US6136528A (en) | Multiple sclerosis virus | |
| EP2868751A1 (en) | HCBI sequences as an early marker for the future development of cancer and diseases of the CNS and as a target for cancer treatment and prevention | |
| EP0485209A1 (en) | Non A, non B hepatitis virus related antigen, antibody detection systems, polynucleotides and polypeptides | |
| JP2000230930A (ja) | Ｈｉｖグル−プに属するレトロウイルス、ｍｖｐ−２９０１／９４、およびその変異体を検出する診断方法及びそのための試験キット並びにワクチン | |
| UA73475C2 (en) | Hepatitis b virus strain, induced by vaccine, nucleic acid isolated molecule coding mutant main surface antiigen of hepatitis b virus, vector and vector system for the preparation of polypeptide, a method for the preparation of polypeptide (variants), purified polypeptide (variants), oligonucleotide, a method for the preparation of antibodies (variants), antibody (variants), a method for the determination of chemical compound for treating the infection of hepatitis b strain infection, a composition, a method for the preparation of composition, a method of organism liquids screening for hepatitis b virus, a method of antibody use, vaccine against hepatitis | |
| JP2005508154A (ja) | 外套細胞リンパ腫の外套組織球から単離されたレトロウイルス | |
| US5254459A (en) | Nucleotide and amino acid sequences of protein MTP40 of M. tuberculosis and synthetic peptides derived therefrom | |
| UA73476C2 (en) | Hepatitus b mutant virus strain, nucleic acid isolated molecule, coding mutant main surface antigen of hepatitus b virus strain, vector and vector system for the preparation of polypeptide, a method for the preparation of polypeptide (variants), purified polypeptide (variants), oligonucleotide, a method for the preparation of antibodies (variants), antibody (variants), a method for the determination of chemicalcompound for the treatment of infection of hepatitis virus strain, a composition, a method for screening of liquids of organism for hepatitis b virus, vaccine against hepatitis | |
| US20070092936A1 (en) | Severe acute respiratory syndrome | |
| Bodjo et al. | Mapping and structural analysis of B-cell epitopes on the morbillivirus nucleoprotein amino terminus | |
| EP0550500A1 (en) | NUCLEOTIDE AND AMINO ACID SEQUENCES OF PROTEIN MTP40 OF $i(M. TUBERCULOSIS) AND SYNTHETIC PEPTIDES DERIVED THEREFROM | |
| US6787142B2 (en) | Mutant human hepatitis B viral strain and uses thereof | |
| US10596237B2 (en) | Identification of pneumocystis antigens and uses thereof | |
| JPH04126085A (ja) | ネコ免疫不全ウイルスの遺伝子ｒｎａに相補性を示すｄｎａ | |
| Wedege et al. | Redesignation of a purported P1. 15 subtype-specific meningococcal monoclonal antibody as a P1. 19-specific reagent | |
| EP0541089A2 (en) | cDNA of human hepatitis C virus, its clone and use thereof | |
| RU2270863C2 (ru) | Мутантный штамм вируса гепатита в и его применение | |
| Schein et al. | Synthetic protein antigens for COVID-19 diagnostics | |
| ES2528738T3 (es) | Método para potenciar la eficacia de una preparación de un anticuerpo monoclonal | |
| Sepulveda et al. | BIOINFORMATIC ANALYSIS OF PARACOCCIDIOIDES BRASILIENSIS 27 KDA ANTIGEN | |
| Lennerstraud | Assays for reverse transcriptase activity andp53 protein. Applications for characterisation of HIV RT mutants and inhibitors, and forp53 expression in breast cancer (Immune deficiency) | |
| Chung | Identifying epitope clusters in equine infectious anemia virus Gag with cytotoxic T lymphocytes from horses with diverse MHC class I alleles | |
| RU2000133299A (ru) | Штамм вируса поствакцинального гепатита B и его применение | |
| JP2005164607A (ja) | 抗クラミジア・ニューモニエ抗体の測定法及びその試薬並びにクラミジア・ニューモニエ感染の診断薬 |